Role of Probiotics as Adjuvant Therapy in Newly Diagnosed Immune Thrombocytopenia in Children

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202311873054587

Enrollment

Registered

2023-11-21

Start date

2023-12-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological Disorders Paediatrics

Interventions

prednisone

prednisone and probiotics

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children aged 1–18 years with primary ITP having platelet count <30,000 /µL

Exclusion criteria

Exclusion criteria: Patients with secondary ITP including leukemia, drugs, lupus erythematous, cirrhosis, HIV, hepatitis C, antiphospholipid syndrome, von-Willebrand factor deficiency. Previous probiotic or antibiotic treatment for the past 4 weeks.

Design outcomes

Primary

Measure	Time frame
early response, initial response, and durable response and remission rates in both groups	—

Secondary

Measure	Time frame
bleeding score , steroid related side effects	—

Countries

Egypt

Contacts

Public ContactMohamed Elshanshory

Professor of Pediatrics

elshanshory@gmail.com+201005680834

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026